KR102718111B1 - 노보비오신 유사체 및 프롤린의 공-결정 형태 - Google Patents

노보비오신 유사체 및 프롤린의 공-결정 형태 Download PDF

Info

Publication number
KR102718111B1
KR102718111B1 KR1020207025571A KR20207025571A KR102718111B1 KR 102718111 B1 KR102718111 B1 KR 102718111B1 KR 1020207025571 A KR1020207025571 A KR 1020207025571A KR 20207025571 A KR20207025571 A KR 20207025571A KR 102718111 B1 KR102718111 B1 KR 102718111B1
Authority
KR
South Korea
Prior art keywords
crystal
proline
ray powder
pharmaceutical composition
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207025571A
Other languages
English (en)
Korean (ko)
Other versions
KR20200141985A (ko
Inventor
신 장
존 알렌 월링
멜라니 제이. 베빌
크리스토퍼 에스. 시딕
자레드 피. 스미트
Original Assignee
리아타 파마슈티컬즈, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리아타 파마슈티컬즈, 아이엔씨. filed Critical 리아타 파마슈티컬즈, 아이엔씨.
Priority to KR1020247033920A priority Critical patent/KR20240155354A/ko
Publication of KR20200141985A publication Critical patent/KR20200141985A/ko
Application granted granted Critical
Publication of KR102718111B1 publication Critical patent/KR102718111B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207025571A 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태 Active KR102718111B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247033920A KR20240155354A (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
US62/627,570 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033920A Division KR20240155354A (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태

Publications (2)

Publication Number Publication Date
KR20200141985A KR20200141985A (ko) 2020-12-21
KR102718111B1 true KR102718111B1 (ko) 2024-10-17

Family

ID=65444361

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207025571A Active KR102718111B1 (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태
KR1020247033920A Ceased KR20240155354A (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247033920A Ceased KR20240155354A (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태

Country Status (19)

Country Link
US (3) US10717755B2 (https=)
EP (1) EP3749675B1 (https=)
JP (3) JP2021512910A (https=)
KR (2) KR102718111B1 (https=)
CN (2) CN118894894A (https=)
AR (1) AR114245A1 (https=)
AU (3) AU2019217821B2 (https=)
BR (1) BR112020016205A2 (https=)
CA (2) CA3226385A1 (https=)
CL (2) CL2020002051A1 (https=)
CO (1) CO2020009761A2 (https=)
EA (1) EA202091885A1 (https=)
IL (2) IL276583B2 (https=)
MX (2) MX2020008326A (https=)
MY (1) MY209803A (https=)
PE (1) PE20211446A1 (https=)
SG (1) SG11202007530XA (https=)
TW (2) TWI868593B (https=)
WO (1) WO2019156907A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276583B2 (en) 2018-02-07 2025-03-01 Reata Pharmaceuticals Inc Crystal structures of proline and a novobiocin analog
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013006651A2 (pt) * 2010-09-23 2017-07-18 Nuformix Ltd composição e cocristal de aprepitante l-prolina
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CN108640910A (zh) * 2011-11-25 2018-10-12 诺弗米克斯技术有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
WO2013119985A1 (en) * 2012-02-09 2013-08-15 University Of Kansas C-terminal hsp90 inhibitors
ES2671478T3 (es) * 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CN106536498A (zh) * 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
HUE052588T2 (hu) * 2014-09-30 2021-05-28 Jiangsu Hengrui Medicine Co Az L-prolin/nátrium-glukóz kotranszporter 2 gátló kristály komplexének kristálya
IL276583B2 (en) 2018-02-07 2025-03-01 Reata Pharmaceuticals Inc Crystal structures of proline and a novobiocin analog

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS Chem. Neurosci., 2015, 6, 1637-1648.

Also Published As

Publication number Publication date
JP2026012851A (ja) 2026-01-27
SG11202007530XA (en) 2020-09-29
AR114245A1 (es) 2020-08-12
JP2021512910A (ja) 2021-05-20
CA3090646A1 (en) 2019-08-15
AU2022283638B2 (en) 2024-07-25
CL2020002051A1 (es) 2021-02-19
CN112020506A (zh) 2020-12-01
IL276583B2 (en) 2025-03-01
US20240043465A1 (en) 2024-02-08
US11401294B2 (en) 2022-08-02
CN118894894A (zh) 2024-11-05
IL276583A (en) 2020-09-30
IL276583B1 (en) 2024-11-01
JP2024001167A (ja) 2024-01-09
PE20211446A1 (es) 2021-08-05
CA3090646C (en) 2024-02-27
TWI868593B (zh) 2025-01-01
TW202510893A (zh) 2025-03-16
WO2019156907A1 (en) 2019-08-15
TWI797249B (zh) 2023-04-01
EA202091885A1 (ru) 2021-01-15
CA3226385A1 (en) 2019-08-15
IL315865A (en) 2024-11-01
EP3749675A1 (en) 2020-12-16
AU2019217821B2 (en) 2022-09-08
CN112020506B (zh) 2024-10-11
US10717755B2 (en) 2020-07-21
AU2022283638A1 (en) 2023-02-02
US20190241599A1 (en) 2019-08-08
MX2020008326A (es) 2020-09-28
BR112020016205A2 (pt) 2020-12-15
KR20240155354A (ko) 2024-10-28
MY209803A (en) 2025-08-05
TW201945381A (zh) 2019-12-01
EP3749675B1 (en) 2025-12-31
CO2020009761A2 (es) 2020-10-30
AU2019217821A1 (en) 2020-09-24
MX2022012856A (es) 2022-11-30
NZ767558A (en) 2024-11-29
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CL2022003784A1 (es) 2023-06-09
AU2024227646A1 (en) 2024-11-14
US20200347088A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
JP5951506B2 (ja) プリン誘導体の結晶性形態
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
US20240043465A1 (en) Co-crystal forms of a novobiocin analog and proline
US20250002474A1 (en) Crystal of pyrrolidine compound
US20180237438A1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
US20260022115A1 (en) Polymorphic forms of a substituted-quinoxaline-type bridged-piperdine compound
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
EA049105B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
TWI915111B (zh) 新生黴素（ｎｏｖｏｂｉｏｃｉｎ）類似物及脯胺酸之共晶型
EA043335B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
KR20240168375A (ko) 고순도 화합물의 제조 방법 및 정제 방법
TW200302830A (en) Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
HK1231046A1 (en) Crystalline forms of a purine derivative
HK1231046B (en) Crystalline forms of a purine derivative

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601